- Home
- CJET vs APLM Comparison
CJET vs APLM Comparison
Compare CJET & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- APLM
- Stock Information
- Founded
- CJET 2009
- APLM 2016
- Country
- CJET China
- APLM United States
- Employees
- CJET N/A
- APLM N/A
- Industry
- CJET Auto Manufacturing
- APLM Blank Checks
- Sector
- CJET Consumer Discretionary
- APLM Finance
- Exchange
- CJET Nasdaq
- APLM Nasdaq
- Market Cap
- CJET 14.3M
- APLM 12.3M
- IPO Year
- CJET N/A
- APLM N/A
- Fundamental
- Price
- CJET $1.76
- APLM $9.56
- Analyst Decision
- CJET
- APLM Strong Buy
- Analyst Count
- CJET 0
- APLM 2
- Target Price
- CJET N/A
- APLM $425.00
- AVG Volume (30 Days)
- CJET 69.5K
- APLM 36.2K
- Earning Date
- CJET 01-28-2025
- APLM 02-15-2025
- Dividend Yield
- CJET N/A
- APLM N/A
- EPS Growth
- CJET N/A
- APLM N/A
- EPS
- CJET N/A
- APLM N/A
- Revenue
- CJET $10,275,000.00
- APLM $2,101,000.00
- Revenue This Year
- CJET N/A
- APLM N/A
- Revenue Next Year
- CJET N/A
- APLM N/A
- P/E Ratio
- CJET N/A
- APLM N/A
- Revenue Growth
- CJET 31.31
- APLM 70.54
- 52 Week Low
- CJET $1.65
- APLM $6.50
- 52 Week High
- CJET $23.94
- APLM $91.00
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- APLM 46.48
- Support Level
- CJET $1.93
- APLM $9.50
- Resistance Level
- CJET $2.08
- APLM $10.67
- Average True Range (ATR)
- CJET 0.17
- APLM 0.92
- MACD
- CJET -0.06
- APLM -0.04
- Stochastic Oscillator
- CJET 10.71
- APLM 13.17
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.